ANDA Submissions — Refuse to Receive for Lack of Justification of Impurity Limits: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 14, 2016
April 21, 2020
29897d63-6e30-44a4-ac28-8fbd517e9e00
Related Documents
Abuse-Deterrent Opioids-Evaluation and Labeling
Guidance DocumentApril 2, 2015Center for Drug Evaluation and Research
Residual Drug in Transdermal and Related Drug Delivery Systems: Guidance for Industry
Guidance DocumentAugust 17, 2011Center for Drug Evaluation and Research
Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation
Guidance DocumentMarch 13, 2013Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox